Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Twelve-Month Natural History of Dark Adaptation in Patients with AMD

Jackson, GR, Clark, ME, Scott, IU, Walter, LE, Quillen, DA and Brigell, MG (2014) Twelve-Month Natural History of Dark Adaptation in Patients with AMD. Optometry & Vision Science: .


PURPOSE: A sensitive endpoint is required for clinical trials evaluating preventative therapies for early age-related macular degeneration (AMD). Dark adaptation (DA) is a sensitive marker of AMD and has been proposed as a potential endpoint. This study evaluated whether significant changes in DA speed could be detected in participants with early to intermediate AMD at 12 months following baseline DA measurement. METHODS: Dark adaptation, visual acuity (VA), and fundus photography were obtained at baseline and at 6 and 12 months in 26 subjects with AMD and in 6 subjects with normal retinal health. Disease severity was assessed by the Nine-Step Age-Related Eye Disease Study AMD severity scale. RESULTS: At 12 months, significant progression of DA impairment occurred in 5 of 26 (19%) participants with AMD. None of the participants with AMD exhibited a significant worsening of fundus grade or decrease of acuity related to disease progression. The normal group exhibited stable DA and VA during the observation period. CONCLUSIONS: Significant worsening of DA was observed in 19% of subjects with AMD in 12 months of observation, despite stable VA and fundus appearance. This study suggests that DA may be a suitable functional endpoint for early clinical studies evaluating novel treatments for early to intermediate AMD

Item Type: Article
Additional Information: NIBR author: Brigell, MG institute: NIBR contributor address: *PhD daggerBS double daggerMD, MPH section signCOA parallelMD Penn State Hershey Eye Center, Penn State College of Medicine, Hershey, Pennsylvania (GRJ, IUS, LEW, DAQ); Department of Ophthalmology, University of Alabama at Birmingham, Birmingham, Alabama (MEC); and Translational Medicine, Novartis Institute for BioMedical Research, Cambridge, Massachusetts (MGB)
Date Deposited: 13 Oct 2015 13:12
Last Modified: 13 Oct 2015 13:12


Email Alerts

Register with OAK to receive email alerts for saved searches.